Dexmethylphenidate

Indications

• FDA-approved for attention-deficit/hyperactivity disorder in patients age 6 years and older as immediate-release tablets and as Focalin XR capsules.
• Azstarys, a fixed combination of the prodrug serdexmethylphenidate with dexmethylphenidate, is approved for ADHD in patients age 6 and older.
• Preferred when a patient responded to racemic methylphenidate but disliked the tablet burden, since equal effect comes at half the milligram dose.
• Focalin XR is a useful once-daily option when the immediate-release form works but wears off before the end of the school or work day.
• Used off-label for narcolepsy and idiopathic hypersomnia, an indication carried by racemic methylphenidate but not by dexmethylphenidate products.
• Used off-label for apathy, fatigue, and cognitive slowing after traumatic brain injury and in medically ill or geriatric depressed adults.

Mechanism of action

• Blocks the dopamine and norepinephrine transporters, increasing synaptic catecholamines in prefrontal cortex and striatum without forcing vesicular release.
• Contains only the d-threo enantiomer, the isomer that carries essentially all transporter affinity in the racemic mixture.
• Because the largely inert l-threo isomer is absent, milligram-for-milligram potency is roughly twice that of racemic methylphenidate.
• Enhanced prefrontal norepinephrine and dopamine tone improves sustained attention, working memory, and response inhibition at moderate doses.
• In Azstarys, serdexmethylphenidate is converted to dexmethylphenidate in the lower gastrointestinal tract, giving delayed second-phase coverage.

Pharmacokinetics

• Immediate-release Tmax is 1-1.5 hours; Focalin XR is bimodal with peaks near 1.5 hours and 6.5 hours from its two bead populations.
• Half-life is about 2.2 hours in children and 3 hours in adults, while clinical coverage is 4-6 hours for IR and roughly 12 hours for XR.
• Metabolized by carboxylesterase CES1A1 to inactive d-ritalinic acid; CYP450 involvement is negligible, so most CYP-based interactions do not apply.
• A high-fat meal delays Focalin XR Tmax by about 1 hour but does not change overall exposure, so it can be taken with or without food.
• About 90 percent of the dose appears in urine as d-ritalinic acid, and protein binding is low, near 12-15 percent.

Dosing

• Immediate-release: start 2.5 mg PO twice daily at least 4 hours apart, raise weekly by 2.5-5 mg/day, maximum 20 mg/day in divided doses.
• When switching from racemic methylphenidate, start at half the total daily methylphenidate dose and retitrate from there.
• Focalin XR: adults start 10 mg each morning to a maximum of 40 mg/day; children 6-17 start 5 mg/day to a maximum of 30 mg/day.
• Azstarys in patients 6-12 starts at 39.2/7.8 mg each morning; adolescents and adults start at the same dose, with a maximum of 52.3/10.4 mg daily.
• Capsules may be opened and sprinkled on applesauce and taken immediately; beads must not be crushed or chewed, which would dump the whole dose.
• No labeled renal or hepatic adjustment; stop for emergent psychosis, unmanageable insomnia, or a sustained rise in blood pressure rather than dose-reduce forever.

Adverse effects

• Decreased appetite in about 30 percent, insomnia in 15-20 percent, headache, abdominal pain, dry mouth, irritability, and jitteriness are common.
• Rebound irritability and hyperactivity as the dose wears off is more noticeable with immediate-release dosing than with the XR form.
• Modest rises in blood pressure and heart rate of roughly 2-4 mmHg and 3-6 bpm, with occasional clinically meaningful hypertension or tachycardia.
• Weight loss and slowed growth velocity in children, so weight and height should be tracked and drug holidays considered if growth deviates.
• New psychosis, mania, or worsening tics can appear at usual doses and warrant stopping the stimulant rather than adding another medication.
• Priapism and peripheral vasculopathy including Raynaud phenomenon are labeled warnings; digital numbness or ulceration requires reassessment.

Monitoring

• Baseline weight, height, pulse, blood pressure, cardiac and family sudden-death history, and screening for tics, psychosis, and substance misuse.
• Repeat vital signs and weight each visit, with height plotted at least every 6 months in children and adolescents on continuous treatment.
• Use ADHD-RS-5, Vanderbilt, or Conners ratings before and after each dose change to separate real benefit from expectancy.
• Ask specifically about end-of-dose rebound, evening appetite return, and sleep onset time, since these drive formulation and timing choices.
• Check the prescription drug monitoring program and reassess misuse or diversion risk at every refill of this schedule II product.

Interactions

• Contraindicated within 14 days of an MAOI, including phenelzine, tranylcypromine, selegiline, and linezolid, because of hypertensive crisis risk.
• May inhibit metabolism of warfarin, phenytoin, phenobarbital, and tricyclic antidepressants, so check levels or INR when these are combined.
• Additive sympathomimetic effects with decongestants, other stimulants, and SNRIs raise blood pressure and heart rate; recheck vitals after adding either.
• Halogenated anesthetics can cause sudden blood pressure and heart rate swings, so hold the dose on the day of an elective procedure.
• Alcohol accelerates release from some extended-release formulations, producing dose dumping and an unintended immediate-release exposure.

Special populations

• Pregnancy: limited data with no clear teratogenic pattern; use only if benefit clearly outweighs risk and prefer nonpharmacologic strategies first.
• Lactation: methylphenidate enantiomers pass into milk in very low amounts, and most infants tolerate maternal treatment without observed effects.
• Pediatric: labeled from age 6; use in children under 6 is off-label and behavioral parent training should be first-line at that age.
• Geriatric: no dedicated studies, so start at the lowest dose and monitor blood pressure, arrhythmia, appetite, and sleep closely.
• Renal and hepatic impairment: no dose adjustment is labeled since clearance depends on carboxylesterase rather than hepatic CYP or renal excretion of drug.

Clinical pearls

• Dexmethylphenidate 10 mg roughly equals racemic methylphenidate 20 mg; halve the dose when switching.
• Focalin XR peaks twice, so an early afternoon slump often means timing, not dose, is the problem.
• Azstarys reaches full effect faster than most prodrug stimulants because part of the dose is already active.